دورية أكاديمية
Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairment.
| العنوان: | Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairment. |
|---|---|
| المؤلفون: | Vega JN; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA., Newhouse PA; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.; Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System, Nashville, TN, USA., Conley AC; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA., Szymkowicz SM; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA., Gong X; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA., Cote S; Department of Population Health Sciences, Division of Health Systems Innovation and Research, University of Utah School of Medicine, Salt Lake City, UT, USA., Mayer I; Department of Medicine, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Taylor WD; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.; Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System, Nashville, TN, USA., Morimoto SS; Department of Population Health Sciences, Division of Health Systems Innovation and Research, University of Utah School of Medicine, Salt Lake City, UT, USA. |
| المصدر: | Digital health [Digit Health] 2023 Aug 13; Vol. 9, pp. 20552076231192754. Date of Electronic Publication: 2023 Aug 13 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: SAGE Publications Ltd Country of Publication: United States NLM ID: 101690863 Publication Model: eCollection Cited Medium: Print ISSN: 2055-2076 (Print) Linking ISSN: 20552076 NLM ISO Abbreviation: Digit Health Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Thousand Oaks, CA] : SAGE Publications Ltd, [2015]- |
| مستخلص: | Purpose: Chemotherapy-related cognitive impairment (CRCI) is a distressing and increasingly recognized long-term sequela reported by breast cancer patients following cancer treatment. There is an urgent but unmet clinical need for treatments that improve CRCI. In this context, we proposed the use of a novel cognitive enhancement strategy called Neuroflex to target CRCI experienced by breast cancer survivors. Methods: The primary aim of this pilot study was to evaluate the feasibility and acceptability of Neuroflex, a novel digital cognitive enhancement strategy, in breast and gynecologic cancer survivors with CRCI. Secondary analyses focused on whether improvements in performance on Neuroflex were associated with improvement in subjective cognitive complaints and objective cognitive performance measures. Results: Participants ( N = 21) completed an average of 7.42 hours of Neuroflex training per week, an average of 44.5 (±1.01) hours total, and had a 100% completion rate. Participants exhibited significant improvement in self-reported cognitive function as well as significant improvement on tasks of verbal learning and memory and auditory working memory. Participants also exhibited improvement in mood, as well as improvement on a disability assessment. Conclusions: Results demonstrate feasibility and that breast cancer survivors are capable of completing a lengthy and challenging cognitive training program. Secondly, Neuroflex may confer specific cognitive benefits to both self-reported and objective performance. Results strongly support further investigation of Neuroflex in a larger controlled trial to establish efficacy for CRCI symptoms. Further studies may also result in optimization of this digital intervention for women with CRCI. Competing Interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JNV, ACC, SMS, XG, SC, and WDT declare no conflicts of interest. SSM receives research funding from NIH and Scientific Advisory Board compensation from Otsuka Pharmaceuticals. PAN has received institutional research funding from NIH, Novartis, and Eisai. IM received institutional research funding from Novartis, Genentech, and Pfizer and received Advisory Board compensation from Novartis, Genentech, Lilly, Astra-Zeneca, GSK, Immunomedics, Macrogenics, and Seattle-Genetics and currently works for Astra-Zeneca. This research was conducted prior to Dr. Mayer’s departure from VUMC. (© The Author(s) 2023.) |
| فهرسة مساهمة: | Keywords: Chemotherapy-related cognitive impairment; Neuroflex; breast cancer; clinical trial; cognitive impairment; digital cognitive interventions; digital medicine; neuroplasticity-based cognitive remediation; survivorship |
| تواريخ الأحداث: | Date Created: 20230817 Latest Revision: 20230918 |
| رمز التحديث: | 20230919 |
| مُعرف محوري في PubMed: | PMC10426301 |
| DOI: | 10.1177/20552076231192754 |
| PMID: | 37588161 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!